Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
SLXN
SLXN
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
SLXN News
Silexion Therapeutics Announces 1-for-10 Reverse Stock Split
5d ago
seekingalpha
Silexion Announces 1-for-10 Reverse Stock Split
5d ago
Newsfilter
HCW Biologics Stock Surges 129% Amid Concerns
May 21 2026
NASDAQ.COM
Silexion Therapeutics Q1 Earnings Beat Expectations
May 18 2026
seekingalpha
Israeli Ministry Approves Silexion's Clinical Trial for SIL204
May 18 2026
Newsfilter
Silexion Therapeutics Signs New Financing Agreement
May 15 2026
seekingalpha
Silexion Therapeutics Completes Financing Agreement
May 15 2026
Newsfilter
Silexion Reports Positive Preclinical Findings for SIL204 in KRAS-Mutated Pancreatic Cancer
May 14 2026
Newsfilter
Silexion Therapeutics Reports Q4 Net Loss Increase
Mar 17 2026
seekingalpha
Silexion Finishes Toxicology Studies for SIL204; Phase 2/3 Trial for Pancreatic Cancer Set to Start in Q2
Nov 26 2025
NASDAQ.COM
Silexion Completes Toxicology Studies for SIL204, Plans Phase 2/3 Trial in 2026
Nov 25 2025
Newsfilter
Silexion Therapeutics Meets Nasdaq Listing Standards Again
Sep 25 2025
Newsfilter
Silexion Therapeutics Stock Rises Following Encouraging Preclinical Results for Pancreatic Cancer
Sep 11 2025
Benzinga
What’s Behind the 190% Surge in Silexion Therapeutics Stock (SLXN) Today?
Sep 11 2025
TipRanks
Silexion Therapeutics Shares Encouraging Preclinical Findings on SIL204's Effectiveness and Distribution in Key Metastatic Sites of Pancreatic Cancer After Systemic Delivery
Sep 11 2025
Newsfilter
Silexion Therapeutics Chooses Contract Research Organization to Assist with Upcoming Phase 2/3 Clinical Trials for SIL204
Sep 04 2025
Newsfilter
Show More News
